vimarsana.com

Latest Breaking News On - Graft versus host disease - Page 31 : vimarsana.com

How to support people with Graft-Versus-Host Disease

Leading Transplant Organizations Unite as GVHD Alliance, Announce Inaugural GVHD Day on February 17, 2023

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Itolizumab was associated with high clinical response rates at Day 15 and 29​Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169​Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif. (BUSINESS WIRE) $EQ #GVHD Equillium, Inc.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.